These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 7967735

  • 21. Prognostic factors in myelodysplastic syndromes: analysis of five scoring systems.
    Rubio-Felix D, Giraldo P, Franco E, Gimeno J, Giralt M.
    Hematol Oncol; 1995; 13(3):139-52. PubMed ID: 7622144
    [Abstract] [Full Text] [Related]

  • 22. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.
    Varma N, Varma S.
    Indian J Pathol Microbiol; 2008; 51(1):97-101. PubMed ID: 18417875
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome.
    Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, Park CJ, Seo EJ, Lee KH.
    Leukemia; 2003 Feb; 17(2):305-13. PubMed ID: 12592327
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
    Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, Niscola P, Naso V, Nobile C, Piccioni AL, D'Andrea M, D'Addosio A, Leone G, Venditti A.
    J Clin Oncol; 2013 Jul 20; 31(21):2671-7. PubMed ID: 23796988
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R.
    Crit Rev Oncol Hematol; 2011 May 20; 78(2):150-61. PubMed ID: 20580567
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes.
    Alexandrakis MG, Passam FH, Pappa CA, Sfiridaki K, Tsirakis G, Damilakis J, Stathopoulos EN, Kyriakou DS.
    Leuk Res; 2005 Jan 20; 29(1):41-6. PubMed ID: 15541473
    [Abstract] [Full Text] [Related]

  • 36. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J, Shao ZH, Liu H, Bai J, Cao YR, He GS, Tu MF, Wang XL, Hao YS, Yang TY, Yang CL.
    Chin Med J (Engl); 2004 Jul 20; 117(7):963-7. PubMed ID: 15265365
    [Abstract] [Full Text] [Related]

  • 37. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 20; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 38. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
    Lorand-Metze I, Pinheiro MP, Ribeiro E, de Paula EV, Metze K.
    Leuk Res; 2004 Jun 20; 28(6):587-94. PubMed ID: 15120935
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.